How big is the Ornithine Transcarbamylase Deficiency Treatment Market?

The Ornithine Transcarbamylase Deficiency Treatment Market size is expected to reach USD 0.82 billion in 2024 and grow at a CAGR of 4.30% to reach USD 1.01 billion by 2029. Read More

What is the current Ornithine Transcarbamylase Deficiency Treatment Market size?

In 2024, the Ornithine Transcarbamylase Deficiency Treatment Market size is expected to reach USD 0.82 billion. Read More

Who are the key players in Ornithine Transcarbamylase Deficiency Treatment Market?

Amgen Inc. (Horizon Therapeutics plc), Bausch Health Companies Inc., Ultragenyx Pharmaceutical Inc., Arcturus Therapeutics, Inc. and Zevra Therapeutics (Acer Therapeutics) are the major companies operating in the Ornithine Transcarbamylase Deficiency Treatment Market. Read More

Which is the fastest growing region in Ornithine Transcarbamylase Deficiency Treatment Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029). Read More

Which region has the biggest share in Ornithine Transcarbamylase Deficiency Treatment Market?

In 2024, the North America accounts for the largest market share in Ornithine Transcarbamylase Deficiency Treatment Market. Read More

What years does this Ornithine Transcarbamylase Deficiency Treatment Market cover, and what was the market size in 2023?

In 2023, the Ornithine Transcarbamylase Deficiency Treatment Market size was estimated at USD 0.78 billion. The report covers the Ornithine Transcarbamylase Deficiency Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Ornithine Transcarbamylase Deficiency Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Share

Statistics for the 2023 & 2024 Ornithine Transcarbamylase (OTC) Deficiency Treatment market share, created by Mordor Intelligence™ Industry Reports. Ornithine Transcarbamylase (OTC) Deficiency Treatment share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Single User License

~~$4750~~

Team License

~~$5250~~

Corporate License

~~$8750~~

Buy Now

Book before:

Market Share of Ornithine Transcarbamylase (OTC) Deficiency Treatment Industry

The ornithine transcarbamylase (OTC) deficiency treatment market is consolidated due to key players capturing the bulk of market share globally and regionally. The competitive landscape includes an analysis of a few international and local companies with substantial market shares. Some key players include Amgen Inc. (Horizon Therapeutics PLC), Bausch Health Companies Inc., Ultragenyx Pharmaceutical Inc., Arcturus Therapeutics Inc., Zevra Therapeutics (Acer Therapeutics), iECURE, Danone Group (Nutricia), Abbott, Reckitt Benckiser, Nestle, Moderna Inc., Duchesnay Pharmaceutical Group-DPG (Medunik USA), and Eurocept Pharmaceuticals Holding (Lucane Pharma).

Ornithine Transcarbamylase Deficiency Treatment Market Leaders

Amgen Inc. (Horizon Therapeutics plc)
Bausch Health Companies Inc.
Ultragenyx Pharmaceutical Inc.
Arcturus Therapeutics, Inc.
Zevra Therapeutics (Acer Therapeutics)

*Disclaimer: Major Players sorted in no particular order

Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Share

Market Share of Ornithine Transcarbamylase (OTC) Deficiency Treatment Industry

Ornithine Transcarbamylase Deficiency Treatment Market Leaders

Ornithine-Transcarbamylase (OTC) Deficiency Treatment Market Report Snapshots

Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)